Cargando…
Estado epiléptico pediátrico
INTRODUCTION. Status epilepticus is defined as the situation resulting from the failure of the mechanisms responsible for terminating an epileptic seizure. In 2015, an operational concept was adopted internationally in which two times are identified: a first time, at which treatment must begin (five...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Viguera Editores (Evidenze Group)
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10280723/ https://www.ncbi.nlm.nih.gov/pubmed/36218253 http://dx.doi.org/10.33588/rn.7508.2022196 |
_version_ | 1785060860669984768 |
---|---|
author | Soto-Insuga, Víctor González-Alguacil, Elena García-Peñas, Juan J. |
author_facet | Soto-Insuga, Víctor González-Alguacil, Elena García-Peñas, Juan J. |
author_sort | Soto-Insuga, Víctor |
collection | PubMed |
description | INTRODUCTION. Status epilepticus is defined as the situation resulting from the failure of the mechanisms responsible for terminating an epileptic seizure. In 2015, an operational concept was adopted internationally in which two times are identified: a first time, at which treatment must begin (five minutes for convulsive status, 10-15 minutes for focal and non-convulsive status); and a second time, after which there is considered to be a high risk of subsequent sequelae (30 minutes in the case of the convulsive). It occurs in 3-42/100,000 children per year, who are refractory or super-refractory in 10-40% of cases. DEVELOPMENT. This article will review the different therapeutic options for status, from early treatment at home to the different first-line (benzodiazepines), second-line (phenobarbital, valproic acid, phenytoin, levetiracetam and lacosamide) or third-line treatments, which include both pharmacological (anaesthetics, propofol, ketamine, lidocaine, topiramate, brivaracetam or perampanel) and non-pharmacological (ketogenic diet, immunomodulatory treatments or epilepsy surgery) therapies. CONCLUSIONS. Early identification and treatment of a prolonged crisis are essential to prevent progression to status. Although with fewer sequelae than in adults, status epilepticus in children represents a cause of mortality of up to 3-5%, while 25% of them will develop subsequent epilepsy, as well as a considerable percentage of neurological sequelae. |
format | Online Article Text |
id | pubmed-10280723 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Viguera Editores (Evidenze Group) |
record_format | MEDLINE/PubMed |
spelling | pubmed-102807232023-06-21 Estado epiléptico pediátrico Soto-Insuga, Víctor González-Alguacil, Elena García-Peñas, Juan J. Rev Neurol Revisión INTRODUCTION. Status epilepticus is defined as the situation resulting from the failure of the mechanisms responsible for terminating an epileptic seizure. In 2015, an operational concept was adopted internationally in which two times are identified: a first time, at which treatment must begin (five minutes for convulsive status, 10-15 minutes for focal and non-convulsive status); and a second time, after which there is considered to be a high risk of subsequent sequelae (30 minutes in the case of the convulsive). It occurs in 3-42/100,000 children per year, who are refractory or super-refractory in 10-40% of cases. DEVELOPMENT. This article will review the different therapeutic options for status, from early treatment at home to the different first-line (benzodiazepines), second-line (phenobarbital, valproic acid, phenytoin, levetiracetam and lacosamide) or third-line treatments, which include both pharmacological (anaesthetics, propofol, ketamine, lidocaine, topiramate, brivaracetam or perampanel) and non-pharmacological (ketogenic diet, immunomodulatory treatments or epilepsy surgery) therapies. CONCLUSIONS. Early identification and treatment of a prolonged crisis are essential to prevent progression to status. Although with fewer sequelae than in adults, status epilepticus in children represents a cause of mortality of up to 3-5%, while 25% of them will develop subsequent epilepsy, as well as a considerable percentage of neurological sequelae. Viguera Editores (Evidenze Group) 2022-10-16 /pmc/articles/PMC10280723/ /pubmed/36218253 http://dx.doi.org/10.33588/rn.7508.2022196 Text en Copyright: © Revista de Neurología https://creativecommons.org/licenses/by-nc-nd/4.0/Revista de Neurología trabaja bajo una licencia Creative Commons |
spellingShingle | Revisión Soto-Insuga, Víctor González-Alguacil, Elena García-Peñas, Juan J. Estado epiléptico pediátrico |
title | Estado epiléptico pediátrico |
title_full | Estado epiléptico pediátrico |
title_fullStr | Estado epiléptico pediátrico |
title_full_unstemmed | Estado epiléptico pediátrico |
title_short | Estado epiléptico pediátrico |
title_sort | estado epiléptico pediátrico |
topic | Revisión |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10280723/ https://www.ncbi.nlm.nih.gov/pubmed/36218253 http://dx.doi.org/10.33588/rn.7508.2022196 |
work_keys_str_mv | AT sotoinsugavictor estadoepilepticopediatrico AT gonzalezalguacilelena estadoepilepticopediatrico AT garciapenasjuanj estadoepilepticopediatrico |